{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:22:21Z","timestamp":1790767341932,"version":"4.1.0"},"reference-count":11,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Diazoxide is the first-line treatment for pediatric hyperinsulinemic hypoglycemia (HI). This study aimed to elucidate the pharmacokinetics of diazoxide in children with HI. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We obtained 81 blood samples from 22 children with HI. Measured serum diazoxide concentrations were used for population pharmacokinetic analysis. Patient factors influencing pharmacokinetics were estimated using nonlinear mixed-effects model analysis. Relationships between drug exposure and adverse drug reactions were also investigated. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Diazoxide disposition in the body was described by a 1-compartment model. Oral clearance (CL\/F) and the volume of distribution were proportional to body weight (WT), as expressed by CL\/F in males (liters\/h) = 0.0358 + 0.00374 \u00d7 WT (kg). CL\/F in females was 39% greater than that in males. Steady-state concentrations of diazoxide were similar following twice- and 3 times-daily dosing when the total daily doses were comparable. A patient whose serum diazoxide concentration exceeded 100 \u03bcg\/mL over a 4-month period developed hyperglycemia. No significant correlation was observed between severity of hirsutism and diazoxide concentration. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI. The potential risk of diabetes mellitus and\/or hyperglycemia increases when serum concentrations of diazoxide exceed 100 \u03bcg\/mL.<\/jats:p>","DOI":"10.1159\/000478696","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T21:01:16Z","timestamp":1500325276000},"page":"316-323","source":"Crossref","is-referenced-by-count":23,"title":["Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia"],"prefix":"10.1159","volume":"88","author":[{"given":"Rika","family":"Kizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Kosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonobu","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/08035250600640414"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.148171"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00792.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937010-00003"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732040-00003"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb05714.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197314173"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600560730"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.3.2.225"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.132"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04326.x"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/478696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/478696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:38:46Z","timestamp":1745426326000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000478696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,11,21]]}},"URL":"https:\/\/doi.org\/10.1159\/000478696","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.5208886","asserted-by":"subject"}]},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"value":"1663-2818","type":"print"},{"value":"1663-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}